
Page#1
Table of Contents
Item 8. Financial Statements and Supplementary Data 
(a) Financial Statements
The consolidated balance sheet of Merck & Co., Inc. and subsidiaries as of December 31, 2016 and 2015, and the related consolidated statements of
income, of comprehensive income, of equity and of cash flows for each of the three years in the period ended December 31, 2016, the notes to consolidated
financial statements, and the report dated February 28, 2017 of PricewaterhouseCoopers LLP, independent registered public accounting firm, are as follows:
Consolidated Statement of Income
Merck & Co., Inc. and Subsidiaries
Years
Ended
December
31
($
in
millions
except
per
share
amounts)
 2016  2015  2014
Sales $ 39,807  $ 39,498  $ 42,237
Costs, Expenses and Other 
Materials and production 13,891  14,934  16,768
Marketing and administrative 9,762  10,313  11,606
Research and development 10,124  6,704  7,180
Restructuring costs 651  619  1,013
Other (income) expense, net 720  1,527  (11,613)
 35,148  34,097  24,954
Income Before Taxes 4,659  5,401  17,283
Taxes on Income 718  942  5,349
Net Income 3,941  4,459  11,934
Less: Net Income Attributable to Noncontrolling Interests 21  17  14
Net Income Attributable to Merck & Co., Inc. $ 3,920  $ 4,442  $ 11,920
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders $ 1.42  $ 1.58  $ 4.12
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders $ 1.41  $ 1.56  $ 4.07
Consolidated Statement of Comprehensive Income
Merck & Co., Inc. and Subsidiaries
Years
Ended
December
31
($
in
millions)
 2016  2015  2014
Net Income Attributable to Merck & Co., Inc. $ 3,920  $ 4,442  $ 11,920
Other Comprehensive Income (Loss) Net of Taxes: 
Net unrealized (loss) gain on derivatives, net of reclassifications (66)  (126)  398
Net unrealized (loss) gain on investments, net of reclassifications (44)  (70)  57
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization (799)  579  (2,077)
Cumulative translation adjustment (169)  (208)  (504)
 (1,078)  175  (2,126)
Comprehensive Income Attributable to Merck & Co., Inc. $ 2,842  $ 4,617  $ 9,794
The
accompanying
notes
are
an
integral
part
of
these
consolidated
financial
statements.
69
Page#2
Table of Contents
Consolidated Balance Sheet
Merck & Co., Inc. and Subsidiaries
December
31
($
in
millions
except
per
share
amounts)
 2016  2015
Assets 
Current Assets 
Cash and cash equivalents $ 6,515  $ 8,524
Short-term investments 7,826  4,903
Accounts receivable (net of allowance for doubtful accounts of $195 in 2016
and $165 in 2015) (excludes accounts receivable of $10 in 2015
classified in Other assets) 7,018  6,484
Inventories (excludes inventories of $1,117 in 2016 and $1,569
in 2015 classified in Other assets - see Note 6) 4,866  4,700
Other current assets 4,389  5,140
Total current assets 30,614  29,751
Investments 11,416  13,039
Property, Plant and Equipment (at cost) 
Land 412  490
Buildings 11,439  12,154
Machinery, equipment and office furnishings 14,053  14,261
Construction in progress 1,871  1,525
 27,775  28,430
Less: accumulated depreciation 15,749  15,923
 12,026  12,507
Goodwill 18,162  17,723
Other Intangibles, Net 17,305  22,602
Other Assets 5,854  6,055
 $ 95,377  $ 101,677
Liabilities and Equity 
Current Liabilities 
Loans payable and current portion of long-term debt $ 568  $ 2,583
Trade accounts payable 2,807  2,533
Accrued and other current liabilities 10,274  11,216
Income taxes payable 2,239  1,560
Dividends payable 1,316  1,309
Total current liabilities 17,204  19,201
Long-Term Debt 24,274  23,829
Deferred Income Taxes 5,077  6,535
Other Noncurrent Liabilities 8,514  7,345
Merck & Co., Inc. Stockholders’ Equity 
Common stock, $0.50 par value
Authorized - 6,500,000,000 shares
Issued - 3,577,103,522 shares in 2016 and 2015 1,788  1,788
Other paid-in capital 39,939  40,222
Retained earnings 44,133  45,348
Accumulated other comprehensive loss (5,226)  (4,148)
 80,634  83,210
Less treasury stock, at cost:
828,372,200 shares in 2016 and 795,975,449 shares in 2015 40,546  38,534
Total Merck & Co., Inc. stockholders’ equity 40,088  44,676
Noncontrolling Interests 220  91
Total equity 40,308  44,767
 $ 95,377  $ 101,677
Page#3
Table of Contents
Consolidated Statement of Cash Flows
Merck & Co., Inc. and Subsidiaries
Years
Ended
December
31
($
in
millions)
 2016  2015  2014
Cash Flows from Operating Activities 
Net income  
$ 3,941 $ 4,459 $ 11,934
Adjustments to reconcile net income to net cash provided by operating activities: 
Depreciation and amortization  
5,441 6,375 6,691
Intangible asset impairment charges  
3,948 162 1,222
Charge related to the settlement of worldwide Keytruda
 patent litigation  
625 — —
Foreign currency devaluation related to Venezuela  
— 876 —
Net charge related to the settlement of Vioxx
 shareholder class action litigation  
— 680 —
Gain on divestiture of Merck Consumer Care business  
— — (11,209)
Gain on AstraZeneca option exercise  
— — (741)
Loss on extinguishment of debt  
— — 628
Equity income from affiliates  
(86) (205) (257)
Dividends and distributions from equity method affiliates  
16 50 185
Deferred income taxes  
(1,521) (764) (2,600)
Share-based compensation  
300 299 278
Other  
313 874 34
Net changes in assets and liabilities: 
Accounts receivable  
(619) (480) (554)
Inventories  
206 805 79
Trade accounts payable  
278 (37) 593
Accrued and other current liabilities  
(2,018) (8) 1,635
Income taxes payable  
124 (266) (21)
Noncurrent liabilities  
(809) (277) 190
Other  
237 (5) (98)
Net Cash Provided by Operating Activities  
10,376 12,538 7,989
Cash Flows from Investing Activities 
Capital expenditures  
(1,614) (1,283) (1,317)
Purchases of securities and other investments  
(15,651) (16,681) (24,944)
Proceeds from sales of securities and other investments  
14,353 20,413 15,114
Divestiture of Merck Consumer Care business, net of cash divested  
— — 13,951
Dispositions of other businesses, net of cash divested  
— 316 1,169
Proceeds from AstraZeneca option exercise  
— — 419
Acquisition of Cubist Pharmaceuticals, Inc., net of cash acquired  
— (7,598) —
Acquisition of Idenix Pharmaceuticals, Inc., net of cash acquired  
— — (3,700)
Acquisitions of other businesses, net of cash acquired  
(780) (146) (181)
Acquisition of Bayer AG collaboration rights  
— — (1,000)
Cash inflows from net investment hedges  
29 139 195
Other  
453 82 (80)
Net Cash Used in Investing Activities  
(3,210) (4,758) (374)
Cash Flows from Financing Activities 
Net change in short-term borrowings  
— (1,540) (460)
Payments on debt  
(2,386) (2,906) (6,617)
Proceeds from issuance of debt  
1,079 7,938 3,146
Purchases of treasury stock  
(3,434) (4,186) (7,703)
Dividends paid to stockholders  
(5,124) (5,117) (5,170)
Other dividends paid  
— — (77)
Proceeds from exercise of stock options  
939 485 1,560
Other  
(118) (61) 79
Net Cash Used in Financing Activities  
(9,044) (5,387) (15,242)